Intended Use

The Riptide Aspiration System is intended for use in the revascularization of patients with acute ischemic stroke secondary to intracranial large vessel occlusive disease (within the internal carotid, middle cerebral M1 and M2 segments, basilar, and vertebral arteries) within 8 hours of symptom onset. Patients who are ineligible for thrombolytic drug therapy or who failed thrombolytic drug therapy are candidates for treatment.

Technology

The system comprises React 68 and React 71 catheters, large bore aspiration tubing, an aspiration pump, and collection canister with tubing. It operates by continuous aspiration to remove clots from large intracranial vessels. Components are made of medical grade plastics and metals with hydrophilic coatings; the pump provides vacuum suction with a range of 0-29 inHg and flow rate up to 0.8 SCFM. Electrical safety and medical suction compliance are confirmed per IEC and ISO standards.

Performance

Non-clinical bench testing and design validation performed, including electrical safety, electromagnetic compatibility, medical suction tests, and usability engineering assessments. No clinical testing changes were necessary as the device maintains the same intended use and technology from predicate. Testing confirmed substantial equivalence and safety.

Predicate Devices

No predicate devices specified

Device Timeline

  • 1

    Submission

    9/30/2024

    29 days
  • 2

    FDA Approval

    10/29/2024

Other devices from Micro Therapeutics Inc. d/b/a ev3 Neurovascular

Ready to Sharpen Your Edge?

Join hundreds of your peers who rely on RadAI Slice. Get the essential weekly briefing that empowers you to navigate the future of radiology.

We respect your privacy. Unsubscribe at any time.